Growth hormone, secreted by the pituitary gland, has long been known to influence lifespan. Mice engineered to lack the receptor everywhere in the body are dwarfs, but they are also the longest-lived laboratory mouse strain ever recorded, with enhanced insulin sensitivity and resistance to obesity-driven inflammation. Recent work has refined this picture by deleting the receptor in individual tissues. Removing it from fat cells modestly extends lifespan and improves frailty and cognition in aged mice, while removing it from the liver was previously shown to trigger fat-producing genetic programs and pathological lipid buildup. What remained unclear was whether hepatic growth hormone signaling influences aging itself rather than just metabolism.

To answer that question, the team crossed mice carrying floxed GHR alleles with Albumin-Cre transgenic animals, producing offspring in which the receptor was excised exclusively in hepatocytes. Polymerase chain reaction confirmed that the deletion was confined to the liver and absent from fat, heart, spleen, kidney, lung, brain, and intestine. The researchers then followed cohorts of male and female knockout and control mice for up to two years, feeding some a standard chow diet and others a high-fat diet to test whether metabolic stress would amplify any aging phenotype.

The results in males were dramatic. Survival curves showed that male LiGHR knockout mice died significantly earlier than controls, while females showed no significant difference, hinting at a sex-dependent effect. At 24 months of age, the knockout males weighed less, had sparser fur, and performed worse across a battery of behavioral tests. In the Y-maze, they spent less time exploring a novel arm of the maze; in the Morris water maze, they took longer to find a hidden platform and crossed its former location fewer times; and in the open field test, they traveled shorter distances in the central zone. Together, these assays indicated genuine deficits in spatial learning and memory rather than simple locomotor impairment.

The systemic picture was equally troubling. Serum levels of the proinflammatory cytokines tumor necrosis factor alpha, interleukin-6, and interleukin-1 beta were all elevated, a signature of the chronic low-grade inflammation often called inflammaging. Blood triglycerides and total cholesterol were increased. Micro-computed tomography of the right femur revealed reduced bone mineral density, lower bone volume fraction, and thinner trabeculae, hallmarks of musculoskeletal frailty. Glucose tolerance and insulin tolerance tests showed impaired metabolic resilience. The authors are careful to note an important caveat: because deleting hepatic GHR disrupts the normal feedback loop and raises circulating growth hormone, other tissues with intact receptors are bathed in excess hormone. The model therefore cannot fully separate liver-intrinsic effects from indirect effects of elevated growth hormone acting on fat, muscle, bone, and brain, and the team suggests inducible or reversible knockout strategies to resolve this in future work.

Inside the liver itself, the evidence of accelerated aging was unambiguous. Senescence-associated beta-galactosidase activity was markedly elevated, and the classic senescence markers p16, p21, and p53 were upregulated, along with gamma-H2AX, a marker of DNA damage. Masson’s trichrome staining revealed fibrotic scarring, alpha-SMA and collagen levels rose, and Oil Red O staining showed extensive lipid droplet accumulation. Hepatic triglyceride and cholesterol content climbed with age. A parallel experiment in young adult mice fed a high-fat diet for three months reproduced the pattern: more steatosis, more senescence markers, more fibrosis, worse liver enzymes, and dyslipidemia compared with diet-stressed controls. When the researchers compared 12-month-old knockout mice on chow versus those previously fed a high-fat diet, the diet group showed greater lipid accumulation and higher expression of senescence and inflammatory proteins, supporting a mechanistic link between ectopic lipid deposition and accelerated hepatic aging. In cell culture, knocking down GHR in AML12 hepatocyte-like cells and challenging them with a mixture of oleate and palmitate for a week synergistically increased senescence markers, lipid droplets, and inflammatory gene expression.

The mechanistic trail began in the fat. Because hepatic GHR loss disrupts the growth hormone feedback axis, the knockout mice had elevated serum growth hormone and reduced IGF1. Growth hormone is a potent lipolytic signal, and indeed the subcutaneous and epididymal fat depots of the knockout males were shrunken, with fewer and smaller lipid droplets. Lipolysis proteins including ATGL, HSL, and MGLL were upregulated in fat tissue, the thermogenic marker UCP1 increased, and serum non-esterified fatty acids rose. The liver, meanwhile, ramped up expression of CD36, the fatty acid transporter, providing a doorway for the flood of liberated fat to enter hepatocytes. The result was a perfect storm: fat exported from adipose tissue, actively imported by the liver, and deposited as ectopic lipid that feeds back into senescence and inflammation.

RNA sequencing of liver tissue pinpointed the signaling cascade behind this cascade of damage. Loss of GHR signaling reduced phosphorylation of the transcription factor STAT5b, which normally suppresses the nuclear receptor PPAR gamma. With that brake released, PPAR gamma expression and nuclear translocation increased, and cross-referencing its known target genes with the transcriptomic data highlighted CD36 and, most strikingly, PDK4, whose messenger RNA rose more than sevenfold. Dual-luciferase reporter assays in HEK293T cells confirmed that PPAR gamma directly activates the PDK4 promoter, and mutating the predicted binding motif abolished this activation. Overexpressing STAT5b in AML12 cells lowered both PPAR gamma and PDK4, while silencing PPAR gamma with small interfering RNAs reduced PDK4, cementing a GH-GHR-STAT5b-PPAR gamma-PDK4 axis. Additional pathway analysis showed reduced AMPK phosphorylation and SIRT1 alongside increased mTOR and NF-kappa B activity, indicating that multiple aging-related signaling networks were simultaneously deranged.

PDK4, pyruvate dehydrogenase kinase 4, is a mitochondrial enzyme that throttles glucose oxidation by inhibiting the pyruvate dehydrogenase complex, and it has previously been implicated in fatty liver disease, insulin resistance, and vascular calcification. In the knockout livers, reactive oxygen species accumulated, antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase declined, and transmission electron microscopy revealed mitochondria with ruptured membranes and disorganized cristae. Autophagy markers shifted in a pattern consistent with cellular stress. In cultured cells, Seahorse extracellular flux analysis showed that GHR knockdown plus free fatty acid treatment synergistically suppressed basal respiration, maximal respiratory capacity, ATP production, and spare respiratory capacity, while Mito-Tracker staining exposed grossly abnormal mitochondrial morphology. Lipid overload and mitochondrial failure thus formed a self-reinforcing pathological loop.

The therapeutic payoff came from a PDK4-specific inhibitor. Starting at 20 months of age, the researchers treated knockout and control mice weekly for 16 weeks with the compound at low and high doses. PDK4 levels fell, serum liver enzymes ALT and AST dropped, hepatic fat accumulation diminished, and electron microscopy showed restored mitochondrial ultrastructure with reduced reactive oxygen species. Inflammatory cytokines in blood and liver declined in a dose-dependent manner, fibrosis eased, and the senescence markers p16, p21, and gamma-H2AX were downregulated. Encouragingly, the inhibitor also reduced senescence and inflammation markers in naturally aged control mice, echoing earlier reports that late-life PDK4 inhibition extends median lifespan in aged animals. The authors conclude that hepatic growth hormone receptor signaling, acting through the STAT5b-PPAR gamma-PDK4 axis, is a meaningful contributor to liver aging and a promising target for interventions aimed at extending healthspan, though they caution that the systemic phenotypes likely reflect combined liver-intrinsic and hormone-driven effects that future inducible models will need to disentangle.

Subject of Research: Hepatocyte-specific growth hormone receptor deletion, hepatic mitochondrial dysfunction, and accelerated aging in mice

Article Title: Hepatocyte Growth Hormone Receptor Ablation Is Associated With Aging Phenotypes and Hepatic Mitochondrial Dysfunction

Article References: Yang, K., Jian, Y., Pang, F., Ying, M., Yang, Q., Liu, N., Wang, S., & Wu, Y. (2026). Hepatocyte Growth Hormone Receptor Ablation Is Associated With Aging Phenotypes and Hepatic Mitochondrial Dysfunction. Aging Cell, 25(10), Article e70741. https://doi.org/10.1111/acel.70741

Image Credits: AI Generated

DOI: 10.1111/acel.70741

Keywords: aging, growth hormone receptor, liver, mitochondrial dysfunction, PDK4, PPAR gamma, STAT5b, hepatic steatosis, cellular senescence, inflammaging, knockout mice, lipid metabolism

Sertoli cells are the architectural and metabolic backbone of the seminiferous tubules, the coiled structures inside the testis where sperm are made. Each Sertoli cell extends from the basement membrane to the tubule lumen and physically cradles developing germ cells at every stage of their maturation, from spermatogonial stem cells through spermatocytes and spermatids to fully formed sperm. Beyond structural support, these cells supply nutrients, regulate the local hormonal environment, and maintain the polarity of the seminiferous epithelium. They also perform a housekeeping task that is easy to overlook: phagocytosing residual bodies, the excess cytoplasm discarded by spermatids as they transform into streamlined spermatozoa. Without this continuous clearance and recycling, the tubule becomes cluttered and germ cell development stalls.

A defining structure in this system is the blood-testis barrier, a constellation of tight junctions between adjacent Sertoli cells near the base of the tubule. The barrier partitions the seminiferous epithelium into basal and adluminal compartments, shielding meiotic and post-meiotic germ cells from the bloodstream and from the immune system, which would otherwise recognize haploid sperm antigens as foreign. The integrity of this barrier depends on junctional proteins such as Claudin-11, a claudin family member that is highly expressed in Sertoli cells and is required for normal barrier function. Disrupting the barrier does not merely expose germ cells to immune attack; it also destabilizes the polarized architecture that germ cells need to advance through the epithelium.

Beclin1, encoded by the Becn1 gene, is a core component of the autophagy initiation complex. Autophagy begins when a cup-shaped membrane, the phagophore, sequesters cytoplasmic cargo and seals into a double-membraned autophagosome, which then fuses with lysosomes for degradation. Beclin1 partners with the lipid kinase PIK3C3 (also known as VPS34) to nucleate this process, and its activity is modulated by interacting proteins such as Rubicon, which suppresses autophagic degradation, and ULK1, which initiates it. Because complete loss of Beclin1 is lethal early in embryonic development, researchers have had to rely on tissue-specific knockout strategies to probe its function in adult organs, and the testis has proven a particularly informative setting.

The Beijing team, led by Yuqing Cai and corresponding authors Yinghe Qin and Yingjie Wu, generated mice in which Becn1 was deleted only in Sertoli cells. The conditional knockout males were fertile in early adulthood, but their reproductive performance declined sharply. At nine weeks of age—the onset of full sexual maturity in the mouse—they sired fewer offspring and produced sperm of reduced quality. Histological examination of their testes revealed vacuolated seminiferous tubules, a hallmark of epithelial disorganization in which fluid-filled cavities disrupt the orderly layers of germ cells. By twelve weeks, the mice were completely infertile, indicating a progressive degeneration rather than a static developmental defect.

The cellular explanation for this collapse lay in two interlocking failures. First, the blood-testis barrier was compromised: the knockout testes showed disrupted barrier integrity and reduced expression of Claudin-11, the tight junction protein that helps seal the epithelium. Second, autophagy itself was clearly impaired. The researchers measured the ratio of LC3-II to LC3-I, a standard biochemical readout of autophagosome formation in which the soluble LC3-I protein is lipidated to membrane-bound LC3-II as autophagosomes assemble. In the absence of Beclin1, this ratio fell, demonstrating that Sertoli cells could no longer form autophagosomes efficiently. The autophagic flux that normally clears damaged organelles, protein aggregates and phagocytosed residual bodies had been throttled at its initiation step.

These results dovetail with a growing body of evidence that autophagy is not a generic housekeeping pathway in the testis but a process with specific, stage-specific reproductive duties. Previous work has shown that the autophagy protein ATG5 is required for the development of elongating spermatids, sperm individualization and normal male fertility, while Atg7 is essential for acrosome biogenesis, the construction of the enzyme-filled cap that sperm need to penetrate an egg. In Sertoli cells, autophagy has been implicated in the assembly of ectoplasmic specializations, the actin-based adhesive junctions that anchor spermatids, and in the regulation of cell polarity through PIK3C3’s control of the actin-severing protein scinderin. Conversely, the autophagy suppressor Rubicon promotes Sertoli cell function by preventing the degradation of the transcription factor GATA4, illustrating that the pathway must be tuned, not merely maximized.

What makes the new study notable is its focus on the initiation machinery rather than the downstream execution proteins. Earlier work from the same group had shown that Beclin1 is vital for spermatogenesis and male fertility when studied more broadly; the present study sharpens the picture by deleting the gene exclusively in Sertoli cells and tracing the resulting pathology to barrier disruption and failed autophagosome formation. This matters because Sertoli cell dysfunction is increasingly recognized as a contributor to unexplained male infertility in humans. While many cases of poor sperm quality are attributed to the germ cells themselves, the new data reinforce the idea that the somatic niche can be the primary fault line: when the nurse cells falter, the germ cells they support fail secondarily.

The study also connects autophagy to the metabolic economics of the tubule. Sertoli cells metabolize glucose into lactate, which they export to germ cells as a preferred fuel, and recent work in Tibetan sheep has shown that BECN1-mediated autophagy activates the glycolytic pathway that drives this lactate synthesis. A Sertoli cell stripped of Beclin1 may therefore be compromised not only in waste clearance and junction maintenance but also in metabolic provisioning, compounding the stress on developing germ cells. The vacuolation observed in the knockout tubules is consistent with such a multi-system failure, in which barrier breakdown, impaired phagocytosis and metabolic shortfall reinforce one another.

For now, the findings are confined to mice, and translating them to human fertility medicine will require caution. Yet they suggest concrete directions for research: screening for impaired autophagic flux in Sertoli cells of infertile men, exploring whether environmental factors known to perturb autophagy also affect barrier integrity, and investigating whether pharmacological modulation of the pathway could protect the niche. The work, supported by approved animal protocols at China Agricultural University and published as an open record with all data contained in the article, adds Beclin1 to the short list of genes whose deletion in Sertoli cells alone is sufficient to render a male mouse infertile. In the intricate economy of the seminiferous tubule, it appears the janitors are as indispensable as the workers they serve.

Subject of Research: The role of the autophagy protein Beclin1 in Sertoli cell function and mouse spermatogenesis

Article Title: Beclin1 Regulates Sertoli Cell Function to Maintain Mouse Spermatogenesis

Article References: Beclin1 Regulates Sertoli Cell Function to Maintain Mouse Spermatogenesis. (n.d.). https://doi.org/10.1007/s43032-026-02202-8

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02202-8

Keywords: autophagy, Beclin1, Sertoli cells, spermatogenesis, blood-testis barrier, male infertility, Claudin-11, LC3, knockout mice, sperm quality, seminiferous tubules, reproductive biology

MROH1, also known as HEATR7A, first drew attention from work on the humble roundworm Caenorhabditis elegans. Researchers had identified the worm protein HPO-27, a HEAT repeat protein, as a critical mediator of lysosomal membrane scission. When HPO-27 is lost, the worm’s tissues fill up with aberrant tubular lysosomal networks instead of the usual discrete vesicles. The mammalian homologue MROH1 was subsequently shown to interact with the WASH–actin machinery to regulate lysosomal fission, positioning it as a gatekeeper of lysosomal integrity. What remained entirely unknown was whether this housekeeping role had any physiological relevance for hormone-producing tissues, and no prior study had ever connected MROH1 to thyroid biology.

A crucial clue came from human gene expression databases. Transcriptomic profiling across the GTEx portal and the Human Protein Atlas classifies MROH1 as markedly tissue-enhanced in the thyroid gland relative to other organs—striking preferential expression for a core component of the lysosomal fission machinery. That observation prompted the Tsukuba team, led by Nami Ohuchi and Yoshinori Osaki under the supervision of Hitoshi Shimano, to generate a global MROH1 knockout mouse line. Sperm carrying the Mroh1(tm1a(KOMP)Wtsi) allele were obtained from the European Mouse Mutant Archive, floxed mice were created by Flpe-mediated excision of the gene trap cassette, and ubiquitous deletion of exons 5 through 7 was achieved by crossing with Ayu1-Cre transgenic mice. Cre-negative floxed littermates served as wild-type controls throughout.

The knockout strategy worked as designed: quantitative RT-PCR confirmed the complete absence of Mroh1 transcripts in the thyroids of the deficient animals. To address possible genetic compensation, the team also measured Mroh2a, a close paralog of Mroh1, and found only a non-significant upward trend in its expression. Metabolic phenotyping then produced a subtle but revealing picture. Food intake and body length were unchanged between genotypes, but the knockout mice gained weight gradually, reaching a statistically significant difference by 24 weeks of age. The weight gain occurred independently of altered skeletal growth, suggesting systemic metabolic adaptations rather than a primary effect on development.

The endocrine phenotype emerged clearly when the researchers measured serum hormones. Free thyroxine (FT4) was significantly reduced in knockout mice at both 3 and 6 months of age, while free triiodothyronine (FT3) was significantly lower by 6 months. Serum TSH showed only a non-significant increasing trend—a puzzling feature the authors openly acknowledge, since standard rodent thyroid economy would predict a compensatory TSH rise when circulating hormones fall. Whether the discrepancy reflects altered central feedback, differences in hormone metabolism, or transport effects remains unresolved and will require functional assessment of the hypothalamic–pituitary axis in future work.

Consistent with the well-known clinical association between hypothyroidism and dyslipidemia, total serum cholesterol was comparable at 3 months but significantly elevated in the knockout animals by 6 months, while triglycerides remained unchanged. Importantly, markers of liver and kidney function, blood glucose, and creatine kinase levels were all unremarkable, and histological examination of the lung, brain, liver, and skeletal muscle revealed no overt abnormalities. The thyroid, in other words, stood out as the principal site of pathological consequence—an outcome that mirrors MROH1’s preferential expression in that gland and strengthens the causal narrative.

To understand the structural basis of the hormone deficit, the team turned to histology. At 3 months of age, thyroid morphology in the knockout mice looked essentially normal. By 6 months, however, the gland showed clear architectural remodelling: follicular area was reduced, and follicles were progressively replaced by interstitial cells and adipocyte-like structures. Quantification of the follicle area ratio showed a downward trend that narrowly missed statistical significance, but a more sensitive analysis of individual follicles—over 1,700 follicles measured across both groups—revealed a statistically significant shift towards smaller follicle sizes in the knockout mice (p = 0.0095, Kolmogorov–Smirnov test). The gland, in effect, was quietly remodelling itself at the cellular level long before gross pathology would appear.

Molecular profiling pointed to the transcriptional roots of the defect. Expression of Nkx2-1 and Foxe1, the master regulators of thyroid differentiation, was significantly reduced in the knockout thyroids, with Pax8 and Hhex trending in the same direction. Concurrently, thyroglobulin—the essential precursor of thyroid hormone synthesis—was significantly downregulated, as was Slc16a2 (Mct8), the thyroid hormone transporter. Other genes involved in hormone production, including Tshr, Slc5a5 (Nis), and Slc26a7, showed decreasing trends. This coordinated loss of lineage-defining transcription factors and their functional target genes suggests that MROH1 is required for the long-term maintenance of follicular cell identity and differentiated function, not merely for organelle housekeeping.

What the study did not find is equally telling. Given MROH1’s established role in lysosomal fission and the dependence of hormone release on lysosomal proteolysis, the team fully expected to find impaired lysosomal function. Instead, immunoblotting showed that protein levels of LAMP2, cathepsin L, and cathepsin D were unchanged, and two independent assays—a live-cell fluorogenic substrate assay in primary thyroid cells and an enzymatic activity assay in whole-tissue lysates—revealed no significant difference in cathepsin L activity. The fundamental capacity for lysosomal degradation appeared intact. The authors caution that bulk assays may simply be too blunt to detect localized defects in lysosomal membrane trafficking, and that subtle, progressive endo-lysosomal trafficking failures could still accumulate over time, as seen in the delayed thyroid pathology of lysosomal storage disease models such as cystinosis.

The broader significance is twofold. First, the work establishes MROH1 as a genetic factor for thyroid hormone homeostasis in vivo, with a phenotype distinct from the profound hypothyroidism and goitre seen in complete MCT8 or thyroglobulin knockouts—the partial downregulation of thyroid genes produces a milder, late-onset endocrine defect without gland enlargement. Second, it extends the emerging view that lysosomal membrane dynamics are not merely cellular plumbing but active participants in tissue-level physiology, with the caveat that the precise mechanistic bridge from MROH1 deficiency to transcriptional downregulation remains to be charted. Because the mice carry a congenital deletion yet show a late-onset phenotype, extrathyroidal contributions cannot be excluded. Tissue-specific knockout models, currently the next step for the Tsukuba group, should disentangle the global versus thyroid-specific roles of MROH1—and may ultimately clarify whether subtle lysosomal trafficking defects in humans contribute to mild hypothyroidism, thyroid remodelling, and the cardiovascular risk that follows from unexplained hypercholesterolemia.

Subject of Research: The role of the HEAT repeat protein MROH1 in lysosomal fission and thyroid hormone homeostasis in mice

Article Title: The HEAT Repeat Protein MROH1 Deficiency Leads to Reduced Circulating Thyroid Hormone Levels in Mice

Article References: Ohuchi, N., Osaki, Y., Nakagawa, Y., Miyamoto, T., Araki, M., Mizunoe, Y., Matsuda, T., Murayama, Y., Sugano, Y., Iwasaki, H., Matsuzaka, T., Sekiya, M., & Shimano, H. (2026). The HEAT Repeat Protein MROH1 Deficiency Leads to Reduced Circulating Thyroid Hormone Levels in Mice. Endocrinology, Diabetes & Metabolism, 9(5), Article e70348. https://doi.org/10.1002/edm2.70348

Image Credits: AI Generated

DOI: 10.1002/edm2.70348

Keywords: MROH1, thyroid hormone, lysosomal fission, hypothyroidism, hypercholesterolemia, knockout mice, Nkx2-1, Foxe1, thyroglobulin, cathepsin L, endocrine physiology, University of Tsukuba

That suspicion has been fueled by a striking clinical observation. Reduced GLO1 expression has been reported both in experimental models of metabolic dysfunction-associated fatty liver disease, or MAFLD, and in liver biopsies from patients with the condition. MAFLD, driven by excessive fat storage in the liver, is estimated to affect roughly 24 percent of the United States population and is present in more than 70 percent of patients with type 2 diabetes, making it one of the most common and consequential comorbidities of the modern obesity pandemic. Sustained consumption of high-carbohydrate diets, particularly those rich in fructose, is a major driving factor in the pathogenesis of both obesity and MAFLD, and fructose-containing foods are capable of inducing insulin resistance in humans and metabolic syndrome in mice. Yet despite the clear association between diminished GLO1 and fatty liver disease, a fundamental question remained unanswered: is the loss of GLO1 a cause of the disease, or merely a compensatory response to it?

A new study published in Physiological Reports by a team at the University of Arizona set out to resolve this question directly. Rather than merely observing correlations, the researchers generated whole-body Glo1 knockout mice using CRISPR-SpCas9 genome editing in the C57Bl/6NN strain, targeting exon 3 of the Glo1 gene with guide RNAs to produce frameshift deletions through non-homologous end joining. They then challenged these mice, alongside wild-type controls, with sixteen weeks of a high-fat, high-sucrose diet containing 36 percent fat and 30 percent sucrose, a regimen well documented to induce fatty liver disease and impair glucose tolerance. The team’s initial hypothesis was straightforward: if reduced GLO1 expression contributes to MAFLD, then deleting the gene should exacerbate metabolic dysfunction by increasing MGO-mediated stress. What they found instead was a surprise that reshapes how the field should think about the glyoxalase system.

Contrary to expectations, the knockout mice were substantially protected from hepatic fat accumulation. When wild-type mice consumed the obesogenic diet, they developed substantial hepatic steatosis, with triglycerides building up in the liver as expected. In the Glo1-deficient mice fed the same diet, this triglyceride accumulation was significantly blunted. The protection was specific to the liver: adipose tissue biology was largely unaffected, with no significant differences in adipocyte size, epididymal white adipose tissue mass, or markers of fat tissue injury between genotypes under the high-fat, high-sucrose conditions. Serum triglycerides and beta-hydroxybutyrate, a readout of fatty acid oxidation, varied only with diet and not with genotype, suggesting that the hepatic phenotype was not secondary to altered fat export or whole-body fat burning. The findings point toward a previously unrecognized role for GLO1 in directly regulating hepatic lipid metabolism, positioning the enzyme as an unexpected participant in the biology of fatty liver rather than a passive bystander.

But the metabolic ledger did not balance cleanly. While the knockout mice enjoyed relative protection from fatty liver, their systemic glucose handling deteriorated in a diet-dependent manner. Fasting blood glucose was significantly elevated in high-fat, high-sucrose-fed knockout mice compared with their wild-type counterparts. Oral glucose tolerance testing revealed a significant reduction in the ability of knockout mice to clear systemic glucose when compared with chow-fed controls, and although the difference between the two genotypes on the obesogenic diet did not reach statistical significance in the raw tolerance curves, a deeper analysis told a more troubling story. The constant of glucose decay, calculated from insulin tolerance testing as the rate of glucose disappearance, revealed a significant reduction in insulin responsiveness specifically in the high-fat, high-sucrose-fed knockout mice. Notably, serum insulin levels and hepatic insulin signaling, assessed through phosphorylation of the insulin receptor and AKT, showed no significant differences, indicating that the glucose defect operates independently of measurable changes in insulin activity.

To understand the biochemistry underlying these divergent phenotypes, the researchers turned to sensitive mass spectrometry-based quantification of MGO and its downstream molecular footprints. Free hepatic MGO was not significantly elevated in any treatment group, and the product of GLO1 activity, lactoylglutathione, was significantly reduced in the knockout mice, consistent with the loss of enzyme function. A complicating factor emerged, however: the high-fat, high-sucrose diet produced a marked reduction in hepatic glutathione regardless of genotype, and because glutathione is required for GLO1 activity, the reduction in lactoylglutathione may partly reflect this glutathione depletion. When the team examined MGO-derived post-translational modifications on proteins, the results were equally nuanced. Levels of MGO-hydroimidazolone 1, a signature MGO-derived arginine modification, were not significantly affected by diet or genotype, while carboxyethylarginine was elevated in chow-fed knockout mice. These data contradict previous reports indicating dramatic elevations in MGO-derived modifications under diet-induced metabolic stress, and they suggest that steady-state MGO biology in vivo is more buffered than cell culture experiments would predict.

The study also delivered a decisive verdict on a long-standing controversy in diabetes research. Earlier work using short hairpin RNA to knock down Glo1 reported that reduced GLO1 activity could spontaneously generate pathologies resembling diabetic nephropathy in non-diabetic mice, fueling the idea that GLO1 loss is a primary driver of diabetic kidney disease. The Arizona team therefore reasoned that sixteen weeks of high-fat, high-sucrose feeding would exacerbate kidney injury in their knockout animals. Instead, they found no evidence of renal pathology attributable to GLO1 loss. Kidney glycogen accumulated with the obesogenic diet but was unaffected by genotype, serum urea and creatinine were unchanged across all cohorts, and renal levels of MGO-hydroimidazolone 1, carboxyethylarginine, and 3-nitrotyrosine, a modification associated with oxidative stress, showed no significant differences. These findings independently confirm earlier reports from a separate group that complete genetic deletion of Glo1 fails to reproduce the diabetic kidney phenotype seen with knockdown approaches, and they collectively indicate that loss of GLO1 alone is insufficient to drive diabetic nephropathy.

Why might deleting a detoxification enzyme protect the liver while harming glucose control? The authors offer several mechanistic possibilities grounded in their own prior work. In cultured fibroblasts, they previously showed that loss of GLO1 reduces glucose uptake and glycolytic flux, and that Glo1-deficient cells fail to differentiate into mature adipocytes. If a similar reduction in glycolytic flux occurs in the livers of knockout mice in vivo, it would limit the substrate available for MGO generation, potentially explaining why free MGO and MGO-derived modifications remain largely unchanged despite the absence of the primary detoxification enzyme. Reduced glycolytic flux could also directly limit de novo lipogenesis, the pathway by which the liver converts excess carbohydrate into fat, providing a plausible mechanism for the blunted hepatic triglyceride accumulation. Meanwhile, the concept that MGO is not simply a toxin but a concentration-dependent metabolic signal is gaining traction: modest elevations of MGO have been reported to be protective in cardiac ischemia-reperfusion injury and even stimulatory for tumor growth, while only cytotoxic concentrations far exceeding those measured in vivo cause cell death.

The authors are careful to note the limitations of their work. The dietary intervention was terminated at sixteen weeks, a timepoint at which significant hepatic steatosis is evident but more advanced features of MAFLD, such as frank inflammation and fibrosis, have not yet developed. Whether GLO1 influences disease progression at later stages, including the transition to metabolic dysfunction-associated steatohepatitis, remains unknown and is a focus of ongoing investigation. The study also focused on male mice, leaving potential sex differences unexplored, and it did not evaluate alternative MGO detoxification pathways, such as the aldehyde dehydrogenases and aldose reductase, which are thought to play secondary roles but could become important under chronic metabolic stress. Samples for insulin signaling analysis were collected from fed rather than fasted mice, so the effect of GLO1 on glucose-stimulated insulin secretion could not be assessed.

Even with these caveats, the study carries a clear and provocative message: hepatic lipid accumulation and systemic glycemic control are mechanistically distinct in the absence of GLO1, and the glyoxalase system sits at an unexpected crossroads between the two. For a field that has largely treated MGO as a toxic metabolic accident and GLO1 as a straightforward protective enzyme, the demonstration that complete GLO1 loss limits fatty liver while impairing glucose handling in obese male mice demands a more sophisticated view. Future investigations aimed at deciphering the tissue-specific roles of GLO1 in whole-body glucose tolerance and lipid metabolism may reveal whether the glyoxalase cycle, long relegated to the footnotes of biochemistry textbooks, holds therapeutic potential for one of the most common liver diseases of our time.

Subject of Research: The role of glyoxalase 1 in obesity-associated fatty liver disease, glucose homeostasis, and kidney health in mice.

Article Title: Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice

Article References: Hoffman, E. A., Phoebe, A. M., Trujillo, M. N., Zhang, W. C., Jennings, E. Q., Farrera, D. O., Orlicky, D. J., Rutt, L. N., McCullough, R. L., Huacachino, A. A., Marcinkiewicz, M. M., Snyder, N. W., Bruner, K. R., Payan, K. B., Martinez, D. J. F., Stern, J. H., & Galligan, J. J. (2026). Glyoxalase 1 loss reduces fatty liver but impairs glucose handling in male mice. Physiological Reports, 14(17), Article e71106. https://doi.org/10.14814/phy2.71106

Image Credits: AI Generated

DOI: 10.14814/phy2.71106

Keywords: glyoxalase 1, methylglyoxal, fatty liver disease, MAFLD, glucose tolerance, hepatic triglycerides, glyoxalase cycle, high-fat high-sucrose diet, diabetic nephropathy, glycolysis, post-translational modifications, knockout mice